PAC is a chemical conjugate consisting of an ADCs linker and PROTACs linked to an antibody. When PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) in comparison to PROTAC alone.
PROTAC BRD4 degrader for PAC-1 (compound 5) is a chimeric BET degrader GNE-987 conjugated with a disulfide-containing linker[1]. This PROTAC-linker conjugate specifically targets and degrades BRD4, enabling selective proteolysis of PAC-1.
5’-O-DMT-PAC-dA can be used in the synthesis of oligoribonucleotides[1]. [1]. Schulhof JC, et, al. The final deprotection step in oligonucleotide synthesis is reduced to a mild and rapid ammonia treatment by using labile base-protecting groups. Nucleic Acids Res. 1987 Jan 26;15(2):397-416.
(Rac)-Upacicalcet is a racemate of Upacicalcet, which serves as an intravenous calcimimetic agent. Upacicalcet acts by directly targeting calcium-sensing receptors on parathyroid cell membranes, effectively suppressing the release of excessive parathyroid hormone (PTH) and reducing blood PTH levels. This compound holds the potential for researching secondary hyperparathyroidism (SHPT) [1].